Ticker > Company >

Remus Pharmaceutical share price

Remus Pharmaceuticals Ltd.

NSE: REMUS SECTOR: Trading  12k   32   2

2536.65
+56.65 (2.28%)
NSE: 08 Nov 03:40 PM

Price Summary

Today's High

₹ 2550

Today's Low

₹ 2490

52 Week High

₹ 2834.75

52 Week Low

₹ 1200

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1494.59 Cr.

Enterprise Value

1472.19 Cr.

No. of Shares

0.59 Cr.

P/E

88.86

P/B

17.28

Face Value

₹ 10

Div. Yield

0.24 %

Book Value (TTM)

₹  146.78

CASH

23.85 Cr.

DEBT

1.44 Cr.

Promoter Holding

70.84 %

EPS (TTM)

₹  28.55

Sales Growth

41.02%

ROE

33.24 %

ROCE

41.31%

Profit Growth

97.81 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year41.02%
3 Year51.07%
5 YearNA

Profit Growth

1 Year97.81%
3 Year154.05%
5 YearNA

ROE%

1 Year33.24%
3 Year56.91%
5 Year50.28%

ROCE %

1 Year41.31%
3 Year67.75%
5 Year59.97%

Debt/Equity

0.0175

Price to Cash Flow

616

Interest Cover Ratio

71.9887

CFO/PAT (5 Yr. Avg.)

0.553007125580179

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 70.84 0.00
Mar 2024 70.60 0.00
Sep 2023 69.61 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 51.0659299420967% for the Past 3 years.
  • The company has significantly decreased its debt by 6.5032 Cr.
  • Company has been maintaining healthy ROE of 56.9141666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 67.7536333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 71.9887.
  • The company has an efficient Cash Conversion Cycle of -13.5552 days.
  • Company has a healthy liquidity position with current ratio of 3.5763.
  • The company has a high promoter holding of 70.84%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.6984370129087.

 Limitations

  • Company has contingent liabilities of 75.35 Cr.
  • The company is trading at a high EV/EBITDA of 60.6122.

Quarterly Result (All Figures in Cr.)

Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 11.92 18.42 24.7 45.03 63.5
Total Expenditure 11.53 17.66 20.57 34.48 43.45
Operating Profit 0.39 0.76 4.14 10.55 20.04
Other Income 0.85 0.81 0.72 1.58 3.69
Interest 0.04 0.04 0.09 0.23 0.32
Depreciation 0.11 0.18 0.15 0.48 0.9
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.09 1.36 4.61 11.41 22.52
Tax 0.28 0.33 1.18 2.91 5.71
Net Profit 0.81 1.03 3.43 8.5 16.82
Adjusted EPS (Rs.) 2.03 2.56 8.59 19.59 28.55

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 0.01 0.01 1 1.09 1.47
Total Reserves 2.01 3.04 5.58 18.05 80.59
Borrowings 0.28 0.19 0.1 7.09 1.23
Other N/C liabilities 0.05 0.06 -0.04 0.15 -0.38
Current liabilities 2.93 7.69 9.18 8.16 14.3
Total Liabilities 5.28 10.99 15.82 34.53 97.21
Assets
Net Block 0.5 0.39 0.31 2.54 2.29
Capital WIP 0 0 0 0.02 0.01
Intangible WIP 0 0 0 0 0
Investments 0 0.07 3.07 20.62 43.12
Loans & Advances 0.01 3.03 4.75 0.01 0.64
Other N/C Assets 0 0 0 0 0
Current Assets 4.76 7.5 7.69 11.34 51.16
Total Assets 5.28 10.99 15.82 34.53 97.21
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1.09 1.36 4.61 11.41 22.52
Adjustment 0.21 0.14 0 0.17 -1.02
Changes in Assets & Liabilities 0.3 1.7 1.62 -3.27 -12.66
Tax Paid -0.31 -0.36 -1.19 -3 -6.42
Operating Cash Flow 1.3 2.84 5.04 5.31 2.43
Investing Cash Flow -0.56 -3.09 -4.55 -15.19 -20.9
Financing Cash Flow 0.06 -0.12 -0.17 11.77 39.29
Net Cash Flow 0.81 -0.37 0.32 1.89 20.81

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Mar 2024% Sep 2024%
promoters 69.61 70.60 70.84
anar swapnil shah 16.97 16.97 16.97
hemant ishwarlal modi 1.00 1.00 1.00
mansi aadarsh shah 0.07 0.07 0.07
renosen pharmaceuticals ... - - 0.90
roma vinodbhai shah 17.11 17.18 17.18
shah arpit deepakkumar 17.27 17.57 17.63
sonal hemantbhai modi 0.07 0.07 0.07
swapnil jatinbhai shah 16.97 16.97 16.97
vinodkumar gandalal shah 0.05 0.05 0.05
dhruvalben vishal shah 0.03 0.03 -
renosen pharmaceuticals p... 0.07 0.70 -
PARTICULARS Sep 2023% Mar 2024% Sep 2024%
investors 30.39 29.40 29.16
iegfl - multi opportunity... 2.21 2.84 2.94
llp 0.31 - 0.29
rekha gunavanth kumar 1.09 1.09 1.09
chhattisgarh investments ... 2.02 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Remus Pharmaceutical Stock Price Analysis and Quick Research Report. Is Remus Pharmaceutical an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Remus Pharmaceutical stock price today is Rs 2536.65. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Remus Pharmaceutical . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Remus Pharmaceutical has a PE ratio of 88.8596580340284 which is high and comparatively overvalued .

  • Share Price: - The current share price of Remus Pharmaceutical is Rs 2536.65. One can use valuation calculators of ticker to know if Remus Pharmaceutical share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Remus Pharmaceutical has ROA of 25.5332 % which is a good sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Remus Pharmaceutical has a Current ratio of 3.5763 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Remus Pharmaceutical has a ROE of 33.241 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Remus Pharmaceutical has a Debt to Equity ratio of 0.0175 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Remus Pharmaceutical has reported revenue growth of 41.0178 % which is fair in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Remus Pharmaceutical for the current financial year is 31.5669367602939 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Remus Pharmaceutical is Rs 6 and the yield is 0.2419 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Remus Pharmaceutical is Rs 28.5467 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Remus Pharmaceutical in Ticker for free. Also, one can get the intrinsic value of Remus Pharmaceutical by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Remus Pharmaceutical
X